MMC has granted 4 credit points for delegates participating in the CME

Scientific programme highlights - symposia, debates and discussions

  • AGenomics and precision medicine
  • Has the molecular revolution reached the bedside?
  • How much of genomic data has translated into clinical practice?
  • Has targeted therapy fulfilled its promise? (debate)
  • Is precision medicine an achievable goal? (debate)
  • BNew ideas in clinical oncology
  • Therapeutic strategies to harness the peri-operative window
  • Biological principles of metronomic therapy
  • Targeting copper to treat breast cancer
  • Novel PI3 kinase inhibitor: from bench to bedside
  • CNew ideas in basic research
  • Cancer as an infectious disease caused by dead-cell chromatin
  • Clinical implications of apoptotic circulating tumour cells
  • Cancer: but which cell is it anyway?
  • Cancer metastasis: which cell is it anyway?
  • Dead cell chromatin, tumour heterogeneity and therapy resistance
  • DCancer data analysis
  • Omics and big data sets: out of control?
  • How relevant are the randomized controlled clinical trials in clinical practice?
  • EPublic health and cancer statistics
  • Harms of cancer screening
  • Problems and pitfalls in public health research
  • Challenges of HPV vaccination
  • FThe lure of technology
  • Harnessing technology for cancer treatment, who benefits?
  • The politics and economics of novel technologies
  • Advanced technologies and global cancer outcome
  • GHospital day oration and special lectures
  • Prometheus bound - stalling innovation in successful societies
  • Cancer research in need of a scientific revolution
  • Thinking Outside the Box in Cancer Research: Perspectives from the US NCI
  • Future of Oncology: European perspective
  • Fractal geometry in oncogenesis
  • Should the industry reconsider its approach to cancer drug development?
  • HTop abstracts session
  • IGrand discussion
  • A 90 minute session highlighting the key messages from various talks and discussions during the conference and also deliberate a possible cancer agenda for the future. Panelists will include senior faculty, key note speakers and international policy makers.